First presented at the 62nd Annual Society of Toxicology Meeting, the "Implementation of a
Weight of Evidence Carcinogenicity Assessment Aligned with ICH S1B," and "Assessing
N-nitrosamine Potency Classes," presentations are now available to watch on demand.
We are excited to introduce SEND Advantage™ Services. Offering study conversions, compliance services and consulting, our new and refreshed services have been designed to help organizations maintain SEND compliance and more. Watch our on-demand video right now.
Instem CSO, Dr Gordon Baxter, was recently interviewed by Drug Target Review
for an in-depth editorial on Target Safety Assessment.
Join the journey with us by visiting
one of our bi-weekly industry Blogs
New powerful technology and data sharing suite provides a range of translational science solutions
New functionality along with Enhanced Models to Deliver More Efficient and Comprehensive Predictions in Chemical Safety
Instem Secures Portion of €2.5m Grant as Member of Research Consortium Investigating the Mutagenicity of N-nitrosamines
To help you better evaluate our software or services, we believe an initial, no pressure Web session is the way to go.
© 2023 Instem Group of Companies